Rosa Biotech logo white.png
  • White LinkedIn Icon
  • White Twitter Icon

©2019 Rosa Biotech Limited

Privacy policy

Press kit

Search
  • Arne Scott

Rosa Biotech raise £760,000 to develop groundbreaking biosensing platform


The Rosa Biotech team at Unit DX. From left: Arne Scott, Dek Woolfson, Andy Boyce, Jordan Fletcher and Tania LaGambina.

Rosa Biotech has raised £760,000 of Angel investment - one of the largest initial sums raised by a University of Bristol (UoB) spinout - to build out its technology platform. The group of Angel investors include Jon Craton, founder and former CEO of Cramer, and Harry Destecroix, founder of Ziylo and CEO of Unit DX.


From early disease diagnosis to enhancing industrial biotechnology, there is an ever-growing need to analyse complex biological mixtures. Most techniques rely on the expensive and time-consuming process of developing bespoke tests for specific molecules. The team at Rosa take a different approach.


The company's sensing technology is inspired by the highly refined ability of dogs to smell malaria, Parkinson’s and other life-changing diseases. Here, many non-specific sensor molecules are used to detect a signature for a range of different molecules, rather than a specific one. Rosa Biotech's sensor works in a similar way, which has allowed the research team to demonstrate its strong potential for a wide range of sensing and diagnostic challenges.


Professor Dek Woolfson – whose team at the Bristol BioDesign Institute developed the technology – explains: “Over the past 20 years we have learnt how to design new proteins completely from scratch. Some mimic natural proteins, but others are entirely new structures. We built a series of barrel-shaped proteins that resemble receptors of the mammalian olfactory system, but are much simpler, easier to make, and easier to handle.


“It is these barrels that provide the basis for Rosa’s technology. We make arrays of different barrels, load each barrel with a dye, and then expose the array to something that we want to analyse, for instance, a bodily fluid that may show signs of disease. Molecules in the sample dislodge the dyes to different extents across the array. This gives coloured patterns that are analysed using machine learning. By recording patterns for healthy and diseased samples, we hope to build sensors for early-stage diagnosis of disease.”


Rosa has been established to refine, develop and commercialise this technology, and the company is already working with several clinicians and pharmaceutical manufacturers.


Dr Andy Boyce, CEO of Rosa Biotech, said: “The scientific team has developed a sensing platform that is sensitive enough to detect the faint chemical signature given off by chronic diseases, but also versatile enough to be applied to a broad range of sensing challenges. For example, the complex manufacturing process for high-value drugs.”


This work was enough to attract the attention of the South West’s growing biotech investment community. The team have closed an investment round of £760,000 from an experienced group of local business angels, representing one of the largest founding investments in any UoB spinout company.


Dr Harry Destecroix, founder of Ziylo, the glucose sensing company acquired by pharmaceutical giant Novo Nordisk in August 2018, described why he invested: “Rosa is that rare combination of an early-stage company that is built on world-class research and has already started to get traction with end-users. The combination of novel chemistry and machine learning offers huge opportunities for growth.”


Rosa’s investment will be used to grow the team, build out the company's automated platform and demonstrate the utility of the technology to address challenges in new sectors.

128 views